{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:45:00Z","timestamp":1762375500254},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.yebeh.2011.02.005","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T08:41:36Z","timestamp":1300264896000},"page":"691-693","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy"],"prefix":"10.1016","volume":"20","author":[{"given":"M.","family":"Gavatha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Papavasiliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2011.02.005_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70018-8","article-title":"The neurobehavioural comorbidities of epilepsy: can a natural history be developed?","volume":"7","author":"Hermann","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0013-9580.2004.455005.x","article-title":"The use of anti-epileptic drugs-principles and practice","volume":"45","author":"Sander","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/seiz.2000.0503","article-title":"The effects of refractory epilepsy on intellectual functioning in children and adults: a longitudinal study","volume":"10","author":"Bjornaes","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1528-1157.44.s4.3.x","article-title":"Newer antiepileptic drugs and cognitive issues","volume":"44","author":"Aldenkamp","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0040","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yebeh.2009.07.043","article-title":"Six months of post marketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy center in Germany","volume":"16","author":"Wehner","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1528-1157.1999.tb00739.x","article-title":"Newly diagnosed epilepsy in children: presentation at diagnosis","volume":"40","author":"Berg","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.neuropharm.2006.02.002","article-title":"Seeking a mechanism of action for the novel anticonvulsant lacosamide","volume":"50","author":"Errington","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0065","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organisation of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T06:50:58Z","timestamp":1712299858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505011000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1525505011000618"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2011.02.005","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}